Biomarkers in Biological Fluids for Dementia with Lewy Bodies

Overview

Journal Alzheimers Res Ther

Date 2014 Dec 6

PMID 25478030

Citations 13

Authors

Sebastian Schade

Brit Mollenhauer

Affiliations

Soon will be listed here.

Abstract

Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, since there is a great clinical and neuropathological overlap primarily with Alzheimer's disease and Parkinson's disease. Therefore, more specific biomarkers, not only for scientific reasons but also for clinical therapeutic decision-making, are urgently needed. In this review, we summarize the knowledge on fluid biomarkers for DLB, derived predominantly from cerebrospinal fluid. We discuss the value of well-defined markers (β-amyloid, (phosphorylated) tau, α-synuclein) as well as some promising 'upcoming' substances, which still have to be further evaluated.

Citing Articles

Dementia with Lewy bodies - a clinicopathological update.

Bencze J, Seo W, Hye A, Aarsland D, Hortobagyi T Free Neuropathol. 2023; 1.

PMID: 37283665 PMC: 10209855. DOI: 10.17879/freeneuropathology-2020-2613.

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.

Foska A, Tsantzali I, Sideri E, Stefanou M, Bakola E, Kitsos D Medicina (Kaunas). 2022; 58(5).

PMID: 35630029 PMC: 9144333. DOI: 10.3390/medicina58050612.

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies.

Canaslan S, Schmitz M, Villar-Pique A, Maass F, Gmitterova K, Varges D Front Aging Neurosci. 2021; 13:717930.

PMID: 34630068 PMC: 8493247. DOI: 10.3389/fnagi.2021.717930.

Lewy Body Dementias: A Coin with Two Sides?.

Milan-Tomas A, Fernandez-Matarrubia M, Rodriguez-Oroz M Behav Sci (Basel). 2021; 11(7).

PMID: 34206456 PMC: 8301188. DOI: 10.3390/bs11070094.

Nucleus Basalis of Meynert Stimulation for Lewy Body Dementia: A Phase I Randomized Clinical Trial.

Maltete D, Wallon D, Bourilhon J, Lefaucheur R, Danaila T, Thobois S Neurology. 2020; 96(5):e684-e697.

PMID: 33199437 PMC: 7884989. DOI: 10.1212/WNL.0000000000011227.

References

Bonelli S, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M . L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology. 2004; 63(2):376-8. DOI: 10.1212/01.wnl.0000130194.84594.96. View

Mollenhauer B, Esselmann H, Roeber S, Schulz-Schaeffer W, Trenkwalder C, Bibl M . Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J Neural Transm (Vienna). 2011; 118(5):691-7. DOI: 10.1007/s00702-010-0543-z. View

Jellinger K . Neurobiology of cognitive impairment in Parkinson's disease. Expert Rev Neurother. 2012; 12(12):1451-66. DOI: 10.1586/ern.12.131. View

Noe E, Marder K, Bell K, Jacobs D, Manly J, Stern Y . Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord. 2004; 19(1):60-7. DOI: 10.1002/mds.10633. View

Guntert A, Dobeli H, Bohrmann B . High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006; 143(2):461-75. DOI: 10.1016/j.neuroscience.2006.08.027. View

Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F . CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci. 2001; 22(1):77-8. DOI: 10.1007/s100720170055. View

El-Agnaf O, Salem S, Paleologou K, Cooper L, Fullwood N, Gibson M . Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003; 17(13):1945-7. DOI: 10.1096/fj.03-0098fje. View

Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer W, Ciesielczyk B . Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2005; 19(2-3):164-70. DOI: 10.1159/000083178. View

Buerger K, Zinkowski R, Teipel S, Tapiola T, Arai H, Blennow K . Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002; 59(8):1267-72. DOI: 10.1001/archneur.59.8.1267. View

10.

Anderson J, Walker D, Goldstein J, de Laat R, Banducci K, Caccavello R . Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006; 281(40):29739-52. DOI: 10.1074/jbc.M600933200. View

11.

Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C . Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry. 2007; 12(7):671-80. DOI: 10.1038/sj.mp.4001967. View

12.

Toledo J, Cairns N, Da X, Chen K, Carter D, Fleisher A . Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun. 2013; 1:65. PMC: 3893373. DOI: 10.1186/2051-5960-1-65. View

13.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M . EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008; 131(Pt 3):690-705. DOI: 10.1093/brain/awm322. View

14.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

15.

Gomperts S, Rentz D, Moran E, Becker J, Locascio J, Klunk W . Imaging amyloid deposition in Lewy body diseases. Neurology. 2008; 71(12):903-10. PMC: 2637553. DOI: 10.1212/01.wnl.0000326146.60732.d6. View

16.

Shi M, Bradner J, Hancock A, Chung K, Quinn J, Peskind E . Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011; 69(3):570-80. PMC: 3117674. DOI: 10.1002/ana.22311. View

17.

Mollenhauer B, El-Agnaf O, Marcus K, Trenkwalder C, Schlossmacher M . Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med. 2010; 4(5):683-99. DOI: 10.2217/bmm.10.90. View

18.

Ho G, Liang W, Waragai M, Sekiyama K, Masliah E, Hashimoto M . Bridging molecular genetics and biomarkers in lewy body and related disorders. Int J Alzheimers Dis. 2011; 2011:842475. PMC: 3132544. DOI: 10.4061/2011/842475. View

19.

Chandra S, Gallardo G, Fernandez-Chacon R, Schluter O, Sudhof T . Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005; 123(3):383-96. DOI: 10.1016/j.cell.2005.09.028. View

20.

Compta Y, Parkkinen L, OSullivan S, Vandrovcova J, Holton J, Collins C . Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain. 2011; 134(Pt 5):1493-1505. PMC: 4194668. DOI: 10.1093/brain/awr031. View